Gluco-incretins regulate Beta-cell glucose competence by epigenetic silencing of fxyd3 expression.

Vallois, David; Niederhäuser, Guy; Ibberson, Mark; Nagaraj, Vini; Marselli, Lorella; Marchetti, Piero; Chatton, Jean-Yves; Thorens, Bernard

Published in:
PLoS ONE

DOI:
10.1371/journal.pone.0103277

2014

Link to publication

Citation for published version (APA):
Vallois, D., Niederhäuser, G., Ibberson, M., Nagaraj, V., Marselli, L., Marchetti, P., Chatton, J-Y., & Thorens, B. (2014). Gluco-incretins regulate Beta-cell glucose competence by epigenetic silencing of fxyd3 expression. PLoS ONE, 9(7), [e103277]. https://doi.org/10.1371/journal.pone.0103277

Total number of authors:
8

General rights
Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: https://creativecommons.org/licenses/

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Gluco-Incretins Regulate Beta-Cell Glucose Competence by Epigenetic Silencing of Fxyd3 Expression

David Vallois¹, Guy Niederhäuser¹, Mark Ibberson¹,², Vini Nagaray³, Lorella Marselli⁴, Piero Marchetti⁴, Jean-Yves Chatton⁵, Bernard Thorens¹*,

¹Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland, ²Vital-IT group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland, ³Lund University Diabetes Center, Malmö, Sweden, ⁴Department of Endocrinology and Metabolism, Ospedale di Cisanello, Pisa, Italy, ⁵Department of Cell Biology and Morphology, University of Lausanne, Lausanne, Switzerland

Abstract

Background/Aims: Gluco-incretin hormones increase the glucose competence of pancreatic beta-cells by incompletely characterized mechanisms.

Methods: We searched for genes that were differentially expressed in islets from control and Glp1r⁻/⁻; Gipr⁻/⁻ (dKO) mice, which show reduced glucose competence. Overexpression and knockdown studies; insulin secretion analysis; analysis of gene expression in islets from control and diabetic mice and humans as well as gene methylation and transcriptional analysis were performed.

Results: Fxyd3 was the most up-regulated gene in glucose incompetent islets from dKO mice. When overexpressed in beta-cells Fxyd3 reduced glucose-induced insulin secretion by acting downstream of plasma membrane depolarization and Ca²⁺ influx. Fxyd3 expression was not acutely regulated by cAMP raising agents in either control or dKO adult islets. Instead, expression of Fxyd3 was controlled by methylation of CpGs present in its proximal promoter region. Increased promoter methylation reduced Fxyd3 transcription as assessed by lower abundance of H3K4me3 at the transcriptional start site and in transcription reporter assays. This epigenetic imprinting was initiated perinatally and fully established in adult islets. Glucose incompetent islets from diabetic mice and humans showed increased expression of Fxyd3 and reduced promoter methylation.

Conclusions/Interpretation: Because gluco-incretin secretion depends on feeding the epigenetic regulation of Fxyd3 expression may link nutrition in early life to establishment of adult beta-cell glucose competence; this epigenetic control is, however, lost in diabetes possibly as a result of gluco-incretin resistance and/or de-differentiation of beta-cells that are associated with the development of type 2 diabetes.

Introduction

The gluco-incretin hormones GLP-1 and GIP play multiple roles in the control of glucose homeostasis, in part by acting on pancreatic beta-cells. They potentiate glucose-induced insulin secretion (GIS) [1,2], induce beta-cell proliferation [3,4], protect these cells against cytokine- or glucolipotoxicity-induced apoptosis [5,6], and increase their glucose competence [7]. Their actions depend on their binding to specific Gs protein-coupled receptors [0,9], which induce the production of cAMP leading to activation of protein kinase A, or of the cAMP binding protein Epac2 [10]. Intracellular signaling of the GLP-1 receptor also includes interaction with β-arrestins [11–13]. An important component of the action of GLP-1 is the induction of IGF-1R and IRS-2 expression and activation of the PI3K/Akt signaling pathway by autocrine secretion of IGF-2 and its binding to the IGF-1R [7,14,15].

Type 2 diabetes (T2DM) appears when insulin secretion is no longer sufficient to compensate for peripheral insulin resistance. This is caused by a reduced insulin secretion capacity and a reduction in the total number of beta-cells [16]. Whereas in T2DM patients GIP no longer stimulates insulin secretion GLP-1, at pharmacological concentrations, can still acutely, and glucose-dependently potentiate insulin secretion [17,18]. Newer strategies for the treatment of T2DM therefore aim at increasing GLP-1 signaling. This approach depends on the acute stimulation of insulin secretion and it is still uncertain whether the increase in beta-cell mass and function observed in rodents also takes place in humans. Current evidence rather suggests the opposite since cessation of incretin therapy rapidly leads to re-appearance of hyperglycemia [19]. It is not clear whether the apparent absence
of trophic action on human islets is due to a late initiation of the treatment when beta-cells are already severely dysfunctioned or whether human beta-cells respond to gluco-incretin hormones in a different manner than rodent beta-cells. It is therefore important to better understand the molecular action of gluco-incretins on beta-cells.

In previous studies, we showed that islets from Gipr−/−; Glp1r−/− (dKO) mice had reduced GIS but normal insulin sensitivity [20], increased susceptibility to cytokine-induced apoptosis [15], and reduced glucose competence [7]. These defects were cell-autonomous and maintained when islets were maintained in in vitro cultures. Here, we identify Fxyd3 as the gene that is most overexpressed in dKO islets. Fxyd3 belongs to the Fxyd family of single transmembrane domain containing proteins. These are best known as third subunits of the Na+/K+-ATPase, which can change the affinity of the pump for either Na+ and/or K+ [21]. Fxyd3, also called Mat-8 [22], has a unique topology with two transmembrane domains. It can also associate with the H⁺/K⁺-ATPase, regulate hyperpolarization-activated chloride channels in Xenopus oocytes [22], and its expression is required for the differentiation of the intestinal CaCo2 cell line [23]. It is also overexpressed and may control proliferation of different cancer types [24,25]. In this study, we show that Fxyd3 is a negative regulator of GIS whose expression is negatively regulated by gluco-incretin hormone-dependent promoter methylation, a control that is lost in islets from diabetic mice and humans leading to Fxyd3 overexpression.

Research Design and Methods

Mice

C57BL/6J and Glp1r−/−; Gipr−/− (dKO) mice backcrossed in C57BL/6J background were used. Glp1r−/− and Gipr−/− and dKO mice were littermates obtained by crossing Glp1r+/+; Gipr+/+ heterozygous mice. db/db and db/+ mice were from Janvier (Le Genest/Isee, France). db/db and db/+ mice were 9 weeks old at the time of experiments. Mice were killed by cervical dislocation after isoflurane anesthesia. All experimental procedures received approval from the Service Veterinaire du Canton de Vaud.

Antibodies

Rabbit anti-mouse Fxyd3 was a gift from Pr. K. Geering (University of Lausanne). Goat anti-mouse immunoglobulin antibodies (M-20) were from Santa Cruz Biotechnology (Nunnin- gen, Switzerland); guinea pig anti-insulin antibodies (A0564) from DAKO; rabbit anti-actin antibodies from Sigma (A0066).

Cell Culture

MIN6 cells were from Drs Miyazaki and maintained as described [26]. For transient transfection they were seeded at 0.25.10⁴ cells per well, transfected one day later with Lipofecta- mine 2000 (Invitrogen, Carlsbad, CA) and used 48 h later. Stable transfection was performed with recombinant lentiviruses and G418 selection [27]. For secretion tests, 20 islets or 0.25.10⁴ MIN6 cells were placed in 12-well plates; MIN6 cells were used 4 days later. After a 2 h incubation in Krebs-Ringer bicarbonate HEPES buffer (KRHB, 120 mM NaCl, 4 mM KH2PO4, 20 mM HEPES, 1 mM MgCl2, 1 mM CaCl2, 5 mM NaHCO3, and 0.5% BSA, pH 7.4) containing 2 mM glucose the medium was replaced with KRBH containing 2 or 20 mM glucose for one hour. Insulin was determined by radioimmunoassay (Millipore, Billerica, MA, USA). Intracellular calcium concentrations recording were performed on stably transfected MIN6 cells as described [28].

Primary islets studies

Adult islets were isolated as described [29]. Neonates islets were handpicked from collagenase-digested pancreas. Immunohisto- cence microscopy analysis of islets monolayers seeded on extracellular matrix-coated plates (Novamed, Jerusalem, Israel) was performed as described [29]. Adenoviral transductions of dissociated islets (3 minutes at 37°C in a Hank’s balanced salt solution, 5 mM glucose, 1 mM EGTA) were performed with pAdGFP or pAdFxyd3 adenoviruses (AdEasy system [30]) with a multiplicity of infection of 50. Assays were performed 48 h later.

Bisulfite sequencing

Islet DNA was extracted using the DNeasy Blood and Tissue kit from Qiagen (Hilden, Germany); 500 ng of DNA were converted using Epicentre Bisulfite kit from Qiagen. Then, R1 (+84; −362) and R2 (−655; −1138) regions from the Fxyd3 promoter were PCR amplified (for primers see Table S1) and sub-cloned into TOPO- TA vector (Invitrogen, Carlsbad, CA, USA). Ten clones per region and per mouse were then sequenced in both directions to assess CpG methylation status.

Pyrosequencing

Six regions of the Fxyd3 promoter were PCR amplified (Pyromark PCR kit from Qiagen) with one biotinylated primer (see Table S1) starting from 30 ng of bisulfite-treated DNA. Pyrosequencing was performed on a PSQ 96MA instrument (Qiagen) using Pyromark Gold Reagents from Qiagen. For each human sample 12 regions of the FXYD3 promoter were PCR amplified and pyrosequenced. Primers (Table S2) were designed with the Biotage PSQ Assay Design software and data were analysed by the Pyro Q-CpG software (Qiagen).

Chromatin Immunoprecipitation

Islets were pooled from 4 adult mice per ChIP experiment performed using minor modifications of the micro-ChIP protocol [31]. Islets were lysed with 115 μL of lysis buffer (50 mM Tris-HCl pH 8,0; 10 mM EDTA; 1% SDS; 1 mM PMSF; 20 mM butyrate; protease inhibitors cocktail from Roche) during 20 minutes at 4°C. Samples were then sonicated 3x[20 sec ON/40 sec OFF] and washed with RIPA ChIP buffer (10 mM Tris-HCl pH 7.5; 1 mM EDTA; 1% TX-100; 0,1% SDS; 0,1% Na-deoxycholate; 100 mM NaCl; 1 mM PMSF; 20 mM butyrate; protease inhibitors cocktail). 1 μg of anti-H3K4me3 (Diagenode, Denville, NJ, USA) and 10 μL of agarose beads blocked with sonicated salmon sperm (Millipore, Temecula, CA, USA cat #16–157) were used per ChIP sample. After elution of DNA/Protein/ antibodies complexes, reversal of the crosslinking and proteinase K/RNAse A treatment, DNA was purified using the NucleoSpin kit from Macherey-Nagel (Duren, Germany). For primers used see Table S1.

Luciferase assay

MIN6 cells were seeded at 0.15.10⁴ cells per well in 24-well plates. The day after plating, they were co-transfected with 30 ng of Renilla luciferase vector and 750 ng of the firefly luciferase reporter plasmids using Lipofectamine 2000 (Invitrogen). Firefly and renilla luciferase activities were measured 48 h later with a Glomax Instrument (Promega, Madison, WI, USA). The mouse Fxyd3 promoter (-731 to +19) was cloned into pGL3 basic vector (Promega) or the pCpGL basic, Cpg-free vector (gift from Dr. M. Rehli, Regensburg, Germany). In vitro methylation was performed using SsI and S-adenosyl-methionine (SAM) (New England Biolabs, Ipswich, MA, USA).
Human islet microarray analysis

Human islet RNA was prepared from laser capture microdissected samples and profiled by microarray analysis [32].

Statistical analysis

All experiments were performed at least three times. Results are expressed as means ± sem. Comparisons were performed using unpaired Student’s t test or one-way or two-way ANOVA for the different groups followed by post hoc pair-wise multiple-comparison procedures (Tukey test or Bonferroni, respectively).

Results

Fxyd3 overexpression in islets from dKO mice

Comparative transcriptomic analysis of islets from control and dKO mice [15] revealed Fxyd3 as the most up-regulated mRNA in mutant as compared to control islets (data not shown). Quantitative RT-PCR (Figure 1A) and western blot analysis (Figure 1B) confirmed a three-fold increase in Fxyd3 mRNA and protein expression in islets from adult dKO mice and showed that expression was similar in islets from control or single gluco-incretin receptor knockout mice (Glp1r−/− or Gipr−/− mice). Immunofluorescence microscopy analysis performed on dKO islet cell monolayers showed that FXYD3 expression was expressed at the cell surface (Figure 1C). Quantitative RT-PCR analysis of all the members of the Fxyd family revealed relatively high expression of Fxyd6, intermediate levels of Fxyd3, and very low expression of the other isoforms (Figure 1D). Importantly, only Fxyd3 was differentially expressed in islets from control as compared to dKO mice. These data indicate that in the absence of both gluco-incretin receptors there is a selective overexpression of Fxyd3, which is correlated with decreased GSIS [20].

FXYD3 overexpression impairs glucose-stimulated insulin secretion

To assess whether Fxyd3 overexpression impacts on insulin secretion, we transiently co-transfected MIN6 cells with a Fxyd3 and a human growth hormone (hGH) expression plasmids or with control vectors. The cells were then challenged with low (2 mM) or
Figure 2. Fxyd3 overexpression impairs glucose stimulated insulin secretion in MIN6 cells and primary beta.-cells. (A) MIN6 cells were transiently transfected with a control or Fxyd3 expression plasmid and a plasmid for expression of hGH. Secretion of hGH was then measured at the indicated glucose concentrations. Data are mean ± sem; n = 5 experiments realized in triplicates, ***p<0.001. (B) MIN6 cells stably transfected with a control or Fxyd3 expressing construct were exposed to the indicated concentrations of glucose, KCl or the calcium channel agonist BayK8644. Insulin and hGH secretions were measured in control and Fxyd3 over-expressing cells/islets in multiple experiments. A two-way anova with repeated measurements (pairing each experiment) with post hoc Bonferroni test was used to compare the groups. Data are mean ± sem, n = 10 experiments realized in triplicates, *p<0.05 **p<0.01 ***p<0.001. (C) Western blot analysis of Fxyd3 expression in transiently or stably transfected MIN6 cells. (D, E) Primary islets were isolated from control mice and infected either with LacZ or Fxyd3 adenoviruses. Islets were challenged with the indicated glucose and KCl concentrations. Data are mean ± sem; n = 7 experiments realized in triplicates; **p<0.01). (E) Western blot analysis of Fxyd3 expression in control and Fxyd3 adenoviruses infected islets. (F and G) Intracellular calcium concentrations measured using the Fura2 ratiometric method. Stably control- or Fxyd3-transduced MIN6 cells were superfused with 2 or 20 mM glucose and 30 mM KCl as indicated. (J) Quantification of the calcium response. Data are mean ± sem, n = 20 per group.
doi:10.1371/journal.pone.0103277.g002
high (20 mM) glucose concentrations and hGH secretion was measured. High glucose concentrations induced a 3-fold increased secretion rate in control cells and this was markedly lower in Fxyd3 overexpressing cells (Figure 2A). Separately, we established MIN6 cell lines expressing Fxyd3 or LacZ by lentiviral transduction. Figure 2B shows that insulin secretion was reduced in Fxyd3 expressing as compared to control cells when stimulated by glucose, by KCl, or by the calcium channel agonist BayK8644. The level of Fxyd3 overexpression in transiently and stably transfected MIN6 cells is shown in Figure 2C; there was no detectable expression of FXYD3 in non-transfected MIN6 cells. When recombinant adenoviruses were used to transduce Fxyd3 or GPF in mouse islets overexpression of Fxyd3 significantly impaired glucose- as well as K\(^+\)-induced insulin secretion (Figure 2D). Overexpression of Fxyd3 was verified by western blot analysis (Figure 2E). We next assessed whether glucose-induced raise in intracellular Ca\(^{++}\) concentrations was normal in Fxyd3 overexpressing cells. Figure 2F, G shows that the intracellular calcium concentrations increased similarly in Ctrl and Fxyd3 overexpressing MIN6 cells following a glucose challenge or K\(^+\)-induced depolarization. Together, these results indicate that Fxyd3 overexpression indeed reduces stimulated insulin secretion and that the defect in glucose signaling lays downstream of membrane depolarization and calcium entry.

**Fxyd3 expression is not acutely regulated by the cAMP/ PKA pathway**

Since Fxyd3 is overexpressed when both gluco-incretin receptor genes are inactivated we postulated that Fxyd3 expression could be under negative regulation by the cAMP signaling pathway. We thus tested expression of Fxyd3 in control or dKO islets treated with forskolin for 7, 18 or 48 hours. Neither Fxyd3 mRNA (Figure 3A, C) nor protein (Figure 3B, D) expression was modified in these conditions whereas the expected increased expression of the IGF-1R was observed (Figure 3E). Treatment of control islets with 100 nM exendin-4 for the same periods of time did not modify Fxyd3 mRNA expression (not shown). Thus, these data indicate that activation of the cAMP/PKA pathway does not acutely regulate Fxyd3 expression in adult islets. Instead, they suggest that absence of gluco-incretin signaling induces a permanent change in the regulation of Fxyd3 gene expression. We thus evaluated whether the differential expression of Fxyd3 in islets from dKO vs. control mice was already present at birth or was established during postnatal development. Fxyd3 expression was assessed in islets of 3–4 day-old mice and compared to that of adult control and dKO mice (Figure 3F). Expression of Fxyd3 was slightly higher in islets from neonatal dKO as compared to control mice, although the difference did not reach statistical significance (p = 0.07). However, whereas Fxyd3 expression was reduced in islets from adult as compared to neonatal control mice, no such reduction in expression was observed in the dKO islets.

Thus, Fxyd3 expression is normally suppressed in islets during postnatal development by a gluco-incretin-dependent mechanism distinct from the cAMP/PKA/CREBP transcriptional regulatory pathway.

**Methylation of the Fxyd3 promoter reduces gene transcription**

To determine whether this regulatory events depend on Fxyd3 promoter methylation, a mechanism of gene silencing [33,34], we...
analyzed *Fxyd3* promoter methylation using bisulfite conversion of MeCpGs followed by sequencing. We analyzed two segments of the mouse *Fxyd3* promoter, the R1 region from −362 to +84 and the R2 region from −1138 to −665 (relative to the transcriptional start site +1) (Figure 4A), which were found based on sequence analysis (UCSC genome browser, http://genome.ucsc.edu/) to contain 20 out of the 21 CpGs of this proximal promoter region. Bisulfite conversion efficiency was assessed by measuring the conversion rate of cytosines located outside of CpG sequences and was found to be ~98%. Five CpG were differentially methylated between control and dKO islets at positions −699 (81% in Ctrl vs. 0% in dKO); −280 (59% in Ctrl vs. 22% in dKO); −267 (53% in Ctrl vs. 22% in dKO); −250 (71% in Ctrl vs. 53% in dKO); −219 (94% in Ctrl vs. 56% in dKO) (Figure 4A).
To get quantitative information about the differential methylation of these sites, we used pyrosequencing analysis. Following bisulfite conversion of adult and 3–4 day-old mouse islet genomic DNA, 6 regions were PCR amplified using a biotinylated primer and sequenced. Global methylation level of the \textit{Fxyd3} promoter was the same in islets from control and dKO neonate mice (Figure 4B). This methylation level was not changed during development to the adult stage in dKO islets but was significantly increased in control islets (Figure 4B). Detailed analysis of the methylation patterns (Figure 4C) showed that seven CpGs (−699; −446; −280; −267; −250; −219; −62) were significantly more methylated in control than in dKO adult islets, and the CpGs at positions −699; −446; −280; −219; −62 were more methylated in adult as compared to neonate control islets. In dKO islets, methylation of the CpGs at position −699, −280, −267, −250, −62 was not increased when comparing islets from neonate and adult mice; only those at position −446 and −219 were increased. Thus, in the absence of gluco-incretin receptors a differential methylation of the \textit{Fxyd3} promoter is already evident at 3–4 days of age but is fully established in adult mice.

To determine whether the level of methylation of the \textit{Fxyd3} promoter correlates with transcriptional activity, we determined the degree of association of H3K4me3, a mark of actively transcribed genes [35], with the transcription start site (TSS) of the \textit{Fxyd3} gene using chromatin immunoprecipitation (ChiP) assays. Figure 5A shows a higher presence of H3K4me3 at the TSS of the \textit{Fxyd3} promoter in islets from dKO as compared to control islets. Results are expressed as percent of total input. Data are mean ± sem, n = 3 experiments, *p<0.05. (B) Luciferase activity measured in MIN6 cells transfected with a basic pGL3 or a \textit{Fxyd3} promoter-pGL3 reporter construct. Data are mean ± sem, n = 7 experiments realized in triplicates, ***p<0.001. (C) The same sequence of the mouse \textit{Fxyd3} promoter was sub-cloned into the pCpGL vector (free of CpG). Following in vitro methylation (grey bar) or mock treatment (white bar), basic or \textit{Fxyd3} promoter-pCpGL plasmids were transfected into MIN6 cells and luciferase activity was measured 48 h later. Methylation significantly reduces luciferase activity. Data are mean ± sem, n = 3 experiments realized in triplicates, **p<0.01. (B, C) Plasmids were co-transfected each time with Renilla reporter vector for normalization. doi:10.1371/journal.pone.0103277.g005

\textbf{Figure 5. Hypermethylation of the \textit{Fxyd3} promoter reduces transcriptional activity.} (A) ChiP analysis using H3K4me3 antibody reveals enrichment in this histone mark at the transcriptional start site of the \textit{Fxyd3} gene in dKO as compared to control islets. Results are expressed as percent of total input. Data are mean ± sem, n = 3 experiments, *p<0.05. (B) Luciferase activity measured in MIN6 cells transfected with a basic pGL3 or a \textit{Fxyd3} promoter-pGL3 reporter construct. Data are mean ± sem, n = 7 experiments realized in triplicates, ***p<0.001. (C) The same sequence of the mouse \textit{Fxyd3} promoter was sub-cloned into the pCpGL vector (free of CpG). Following in vitro methylation (grey bar) or mock treatment (white bar), basic or \textit{Fxyd3} promoter-pCpGL plasmids were transfected into MIN6 cells and luciferase activity was measured 48 h later. Methylation significantly reduces luciferase activity. Data are mean ± sem, n = 3 experiments realized in triplicates, **p<0.01. (B, C) Plasmids were co-transfected each time with Renilla reporter vector for normalization.
correlation between their methylation and the level of Fxyd3 mRNA expression. This analysis yielded significant correlation for 7 of these CpGs, all located in the proximal promoter region (–535 to –243) (Table 1). Importantly, 2 of these methylated CpGs, at positions –2177 and –243, were highly correlated with Fxyd3 expression only in diabetic islets (Figure 6I and Table 1).

Discussion

Here, we show that gluco-incretin hormones regulate the expression of Fxyd3, a newly identified regulator of beta-cell glucose competence, by controlling the methylation its promoter. This epigenetic imprinting is established perinatally and partially lost in glucose incompetent islets from diabetic mice and humans, which display increased expression of Fxyd3. Thus, gluco-incretin action early in life contributes to the establishment of the normal insulin secretion capacity of adult islets; loss of this imprinting may contribute to the pathogenesis of type 2 diabetes.

Fxyd3 is a member of the FXYD family of proteins known to regulate ion transporting membrane proteins, which can modulate cellular differentiation, and whose expression is strongly upregulated in some tumors, making it a good cancer biomarker [21,23] [36–39]. Why overexpression of Fxyd3 in beta-cells reduces glucose-stimulated insulin secretion is not yet know. This may be based on the interaction of Fxyd3 with membrane proteins.
and their receptors can influence beta-cells during embryonic activity even in the absence of ligand [41]. Thus, gluco-incretins cells [40]. In addition, GLP-1 receptor has an intrinsic signaling at E17, with both peptides being often co-expressed in the same interesting to note that intestinal GLP-1 and GIP producing cells With respect to the timing of this methylation events, it is already present at most sites. Importantly, however, the was already present at most sites. Importantly, however, the incrmin-dependent methylation of the Fxyd3 promoter was taking place in the perinatal period and is fully established in the adult animals. With respect to the timing of this methylation events, it is interesting to note that intestinal GLP-1 and GIP producing cells appear first at embryonic day 15 [E15], rapidly increase in number at E17, with both peptides being often co-expressed in the same cells [40]. In addition, GLP-1 receptor has an intrinsic signaling activity even in the absence of ligand [41]. Thus, gluco-incretins and their receptors can influence beta-cells during embryonic development and in the perinatal period. In addition, since these methylation events occur perinatally in response to gluco-incretin action, changes in hormonal and nutritional status during pregnancy or early in life may have long-term impact on beta-cell function and the susceptibility to develop diabetes in the adult age.

Epigenetic regulation of gene expression by nutrition and metabolic status is known to modulate the activity of multiple cellular pathways [42]. Nutrition during pregnancy can impact gene expression in offsprings through changes in DNA methylation [43] and similar effects of nutrition during the postnatal period on the susceptibility to develop metabolic disease in the adult age has also been linked to epigenetic modifications [44]. In humans, it has been shown that islets from type 2 diabetic patients display numerous changes in gene methylation patterns [45], and that, in muscle, diabetes is associated with hypermethylation of the Pgc1A promoter and lower gene expression leading to reduced mitochondrial content [46]. Thus, whereas it is well established that DNA methylation regulates gene expression, our study uncovers a so far unrecognized role of gluco-incretins in epigenetic regulation of gene expression that takes place early in life. This could explain preceding observations that administration of GLP-1 to diabetes-prone rats during the first week of life protected them against the development of diabetes in their adult life [47,48]. Although the mechanism of this protection was not established, it may involve epigenetic control of beta-cell function as reported here.

Interestingly, we found Fxyd3 expression was also increased in glucose-unresponsive beta-cells from diabetic mice and humans and that this was correlated with reduced methylation of the Fxyd3 promoter. In db/db mice three of the four sites that were differentially methylated during maturatation of adult islets (positions −699, −219, and −62), and which we propose may have a particularly important role in controlling Fxyd3 expression, displayed significantly reduced methylation. This suggests that the methylation of these sites may be dynamically controlled by gluco-incretin action. Indeed, type 2 diabetes is characterized by beta-cell gluco-incretin resistance [49-51], which may explain the reduced methylation and increased expression of Fxyd3. Alternatively, it has been reported that diabetic hyperglycemia caused beta-cell dedifferentiation as revealed by over expression of transcription factors and enzymes normally present in precursor

### Table 1. Correlation between FXYD3 expression and percent of methylation of individual CpGs.  

| CpG Position | All subjects | Controls | T2D patients |
|--------------|--------------|----------|--------------|
|              | r coeff      | p value  | r coeff      | p value  | r coeff | p value |
| CPG -43      | -0.7219      | 0.0016   | -0.7143      | 0.0576   | -0.9048 | 0.0046 |
| CPG -177     | -0.7353      | 0.0012   | -0.6667      | 0.0831   | -0.9286 | 0.0022 |
| CPG -197     | -0.5588      | 0.0244   | -0.5588      | 0.0244   | -0.5588 | 0.0244 |
| CPG -230     | -0.6265      | 0.0094   | -0.6265      | 0.0094   | -0.6265 | 0.0094 |
| CPG -391     | -0.5412      | 0.0304   | -0.5412      | 0.0304   | -0.5412 | 0.0304 |
| CPG -452     | -0.5029      | 0.0471   | -0.5029      | 0.0471   | -0.5029 | 0.0471 |
| CPG -535     | -0.5971      | 0.0146   | -0.5971      | 0.0146   | -0.5971 | 0.0146 |

DNA from control (n = 8) and T2D (n = 8) human islets were extracted from the same samples as used for the real-time PCR analysis. Then, the 32 CpGs of the FXYD3 promoter from −1 to −1200 were analyzed by pyrosequencing. Correlation analysis between methylation level and FXYD3 expression measured by quantitative RT-PCR was performed for each CpG using the non-parametric Pearson test. 7 CpG sites in the proximal FXYD3 promoter showed significant correlation between methylation level and FXYD3 expression. Within these 7 CpGs, 2 sites showed strongly significant correlation between methylation and FXYD3 mRNA expression only in the T2D group.

doi:10.1371/journal.pone.0103277.t001

controlling beta-cell electrical activity or insulin granule exocytosis. Additional work will clearly be required to answer this question.

We found Fxyd3 to be overexpressed in islets from dKO mice and to negatively regulate glucose competence of insulin secreting cells. Due to the limited information available on Fxyd3 function, we further focused our attention on the unexpected mechanism by which gluco-incretins regulate Fxyd3 expression. Indeed, forskolin treatment, which induces marked accumulation of cAMP in primary beta-cells, did not impact Fxyd3 expression in dKO nor in control islets. Second, overexpression of Fxyd3 in dKO islets was cell-autonomous and maintained in in vitro cultured islets indicating a permanent change in gene expression. Thus, the classical cAMP/PKA signaling pathway that acutely controls gene expression through phosphorylation of CREBP was unlikely to be involved in regulating Fxyd3 expression in adult islets. In neonatal islets, Fxyd3 expression was slightly higher in dKO than in control islets and this initial level of expression was maintained in islets from adult dKO mice but markedly reduced in those of control mice. We therefore suspected that absence of gluco-incretin signaling involved a change in epigenetic control of Fxyd3 expression. Analysis of Fxyd3 promoter methylation revealed differential methylation of seven CpGs in islets from adult control as compared to dKO mice. Chromatin immunoprecipitation analysis showed enrichment of H3K4me3 at the transcriptional start site of Fxyd3 in dKO islets confirming higher transcriptional activity. The inverse relationship between promoter methylation and transcription rate was further supported by the Fxyd3 promoter reporter assays.

In neonatal islets, the difference in Fxyd3 promoter methylation was already present at most sites. Importantly, however, the difference in CpG methylation in control vs. dKO islets markedly increased during the neonatal to adult transition at positions −699, −280, −219, and −62, suggesting that methylation of these sites strongly influenced Fxyd3 transcription rate. Thus, this gluco-incretin-dependent methylation of the Fxyd3 promoter takes place in the perinatal period and is fully established in the adult animals. With respect to the timing of this methylation events, it is interesting to note that intestinal GLP-1 and GIP producing cells appear first at embryonic day 15 [E15], rapidly increase in number at E17, with both peptides being often co-expressed in the same cells [40]. In addition, GLP-1 receptor has an intrinsic signaling activity even in the absence of ligand [41]. Thus, gluco-incretins and their receptors can influence beta-cells during embryonic
cells [52,53]. Our data suggest that this may be accompanied by changes in DNA methylation.

It is not yet clear how gluco-incretins control DNA methylation. In mammals three DNA methyl transferases (Dnmts) catalyze the addition of methyl groups on CpGs [33]. Dnmt1 is responsible for propagation of methylation patterns through cell division cycles. In beta-cells, this enzyme is also required to silence the expression of the transcription factor Arx to prevent their differentiation into alpha cells [54]. Dnmt3a and 3b catalyze de novo methylation. Dnmts expression levels did not differ significantly in islets from dKO or Ctrl mice (not shown). Thus, a modulation of their activity by posttranslational modifications, as reported for Dnmt1 [55,56], rather than changes in expression levels may control the methylation patterns.

In summary, we have identified Fxyd3 as a novel regulator of beta-cell glucose competence. We showed that its expression is initiated at the transcriptional level by gluco-incretin hormone-dependent methylation of its promoter. This epigenetic regulation is initiated in the perinatal period. As secretion of gluco-incretins hormones is controlled by nutrients, the mechanism we describe may link changes in early nutrition to long-term control of beta-cell function. Because this epigenetic regulation is reversed in glucose-unresponsive islets from diabetic mice and humans, which express higher levels of Fxyd3, loss of imprinting of this locus may contribute to beta-cell dysfunction characteristic of type 2 diabetes.

References

1. Holst JJ, Orskov C, Vagn Nielsen O, Schwartz TW (1987) Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut. FEBS letters 211: 169–174.
2. Mojsov S, Weir GC, Habener JF (1987) Insulinotropin: glucagon-like peptide 1-37 co-expressed in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. Journal of clinical investigation 79: 616–619.
3. Perfetti R, Zhou J, Doyle ME, Egan JM (2000) Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 141: 4600–4605.
4. Buteau J, Roduit R, Susini S, Prentki M (1999) Glucagon-like peptide-1 promotes DNA synthesis, activates phospholipidinositols 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1) cells. Diabetologia 42: 856–864.
5. Buteau J, El-Assaad W, Rhodes CJ, Prentki M, Joly E, et al. (2000) Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 43: 806–815.
6. V. Hansotia T, Vusta R, R, F, Hallan PA, et al. (2005) Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278: 471–478.
7. Cornu M, Modi H, Kawamori D, Kulkarni RN, Joffraud M, et al. (2010) GLP-1 promotes beta-cell glucose competence and proliferation by translational induction of insulin-like growth factor-1 receptor expression. J Biol Chem 285: 10538–10545.
8. Thorres B (1992) Expression cloning of the pancreatic beta cell receptor for the glucocorticoid hormone glucagon-like peptide I. Proc Natl Acad Sci USA 89: 8641–8645.
9. Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI (1993) Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 133: 2861–2870.
10. Ozaki N, Shibasaki T, Kushima Y, Miki T, Takahashi K, et al. (2000) cAMP-GEFI is a direct target of cAMP in regulated exocytosis. Nature Cell Biology 2: 805–811.
11. Talbot J, Joly E, Prentki M, Buteau J (2012) beta-Arrestin1-mediated recruitment of c-Src underlies the proliferative action of glucagon-like peptide-1 in pancreatic beta INS832/13 cells. Mol Cell Endocrinol 364: 65–70.
12. Balle S, Ravier MA, Bertrand G (2011) Emerging roles for beta-arrestin-1 in the control of the pancreatic beta-cell function and mass: new therapeutic strategies and consequences for drug screening. Cell Signal 23: 522–528.
13. Jorgensen R, Martini L, Schwartz TW, Elling CE (2005) Characterization of glucagon-like peptide-1 receptor-beta-arrestin 2 interaction: a high-affinity receptor-family. Mol Endocrinol 19: 812–823.
14. Jhala US, Canettieri G, Serratoni RA, Kulkarni RN, Krajevski S, et al. (2003) cAMP promotes pancreatic beta-cells survival via CREB-mediated induction of BDNF. Genes & Development 17: 1575–1580.
15. Cornu M, Yang JY, Jaccard E, Poussin C, Widmann C, et al. (2009) GLP-1 protects Beta-Cells Against Apoptosis by Increasing The Activity Of An Igf2/ Igf1-Receptor Autocrine Loop. Diabetes 58: 1816–1825.

Supporting Information

Table S1 Primers list for mouse Fxyd3 promoter analysis. (DOCX)

Table S2 Primers list for human Fxyd3 promoter analysis. (DOCX)

Acknowledgments

We thank Wanda Dolci, David Tarussio, and Salima Metref from the BT lab for expert technical support. We also gratefully acknowledge the scientific contribution of Sonia Klinger (University of Lausanne) and of Erik Renstrom, Enmin Zhang, and Chen Luan from the Lund University Diabetes Center.

Author Contributions

Conceived and designed the experiments: BT DV. Performed the experiments: DV GN MI VN LM JYC. Analyzed the data: DV MI VN PM JM. Wrote the paper: DV BT.

16. Ashcroft FM, Rorsman P (2012) Diabetes mellitus and the beta cell: the last ten years. Cell 148: 1160–1171.
17. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, et al. (1993) Preserved incretin activity of glucagon-like peptide 1 (7–36amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. Journal of clinical investigation 91: 301–307.
18. Nauck MA, Klein N, Arskov C, Holst JJ, Willms B, et al. (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 741–744.
19. Busek MC, Diazzant M, Correr A, Ellason B, Malloy JL, et al. (2009) One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 32: 762–768.
20. Prentner F, Bircher M, Franklin I, Binnert C, Perdereau M, et al. (2004) Glucokinase and glucagon-like peptide-1 receptor phenotype. Mol Endocrinol 19: 812–823.
30. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, et al. (1998) A simplified system for generating recombinant adeno viruses. Proc Natl Acad Sci U S A 95: 2509–2514.
31. Dahl JA, Collas P (2008) A rapid micro chromatin immunoprecipitation assay (microChIP). Nat Protoc 3: 1032–1045.
32. Marselli L, Thorne J, Dahiya S, Sgroi DC, Sharma A, et al. (2010) Gene expression profiles of Beta-cell enriched tissue obtained by laser capture microdissection from subjects with type 2 diabetes. PLoS ONE 5: e11499.
33. Klose RJ, Bird AP (2006) Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 31: 89–97.
34. Dahl JA, Collas P (2008) A rapid micro chromatin immunoprecipitation assay (microChIP). Nat Protoc 3: 1032–1045.
35. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, et al. (2007) High-resolution profiling of histone methylations in the human genome. Cell 129: 823–837.
36. Ahlers BA, Moorman JR, Rothblum LI, Carl LL, Song J, et al. (2005) Identification of an endogenous inhibitor of the cardiac Na+/Ca²⁺ exchanger, phospholemman. J Biol Chem 280: 19875–19882.
37. Wang J, Ahlers BA, Carl LL, Song J, Rothblum LI, et al. (2006) Cytoplasmic tail of phospholemman interacts with the intracellular loop of the cardiac Na+/Ca²⁺ exchanger. J Biol Chem 281: 32004–32014.
38. Meding S, Balluff B, Elsner M, Schone C, Rauser S, et al. (2012) Tissue-based proteomics reveals FXYD3, S100A11 and GSTM3 as novel markers for regional lymph node metastasis in colon cancer. J Pathol.
39. Zhang Z, Pang ST, Kasper KA, Luan C, Wodarga B, et al. (2011) FXYD3: A Promising Biomarker for Urothelial Carcinoma. Biomark Insights 6: 17–26.
40. Grigoryan M, Kedees MH, Guz Y, Teitelman G (2012) Phenotype of enterocortical L cells becomes restricted during development. Dev Dyn 241: 1896–1902.
41. Serre V, Deloi W, Schaerer E, Soroosh C, Rausch S, et al. (1998) Exendin-(9–39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3’,5’-monophosphate levels and beta-cell glucose competence. Endocrinology 139: 4448–4454.
42. Lu C, Thompson CB (2012) Metabolic regulation of epigenetics. Cell Metab 16: 9–17.
43. Waterland RA, Jirtle RL (2003) Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol 23: 5293–5300.
44. Jimenez-Chillaron JC, Diaz R, Martinez D, Pentinat T, Ramon-Krauel M, et al. (2012) The role of nutrition on epigenetic modifications and their implications on health. Biochimie.
45. Volkmar M, Dedeurwaerder S, Cunha DA, Nidheo MN, Defrance M, et al. (2012) DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients. Embo J 31: 1405–1426.
46. Barres R, Oded ME, Yan J, Ruse A, Fritz T, et al. (2009) Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density. Cell Metab 10: 189–196.
47. Tourrel C, Baille D, Lacorne M, Meile MJ, Kergoat M, et al. (2002) Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the b-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 51: 1443–1452.
48. Tourrel C, Baille D, Meile MJ, Kergoat M, Portha B (2001) Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50: 1562–1570.
49. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ (2011) Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 54: 10–18.
50. Meier JJ, Nauck MA (2010) Is the diminished incretin effect in type 2 diabetes just an epiphenomenon of impaired beta-cell function? Diabetes 59: 1117–1125.
51. Frische A, Stefan N, Hardt E, Haring H, Stumvoll M (2000) Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion. Diabetologia 43: 832–838.
52. Jonas JC, Sharma A, Hasenkamp W, Ikawa H, Patane G, et al. (1999) Chronic hyperglycemia triggers loss of pancreatic beta cell differentiation in an animal model of diabetes. J Biol Chem 274: 14112–14121.
53. Takahashi C, Xuan S, Lin JY, Sussel L, Accili D (2012) Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure. Cell 150: 1223–1234.
54. Dhawan S, Georgiou B, Tsetsis SI, Fan G, Bhasan A (2011) Pancreatic beta cell identity is maintained by DNA methylation-mediated repression of Arx. Dev Cell 20: 419–429.
55. Lavoie G, St-Pierre Y (2011) Phosphorylation of human DNMT1: implication of cyclin-dependent kinases. Biochem Biophys Res Commun 409: 187–192.
56. Sun L, Zhao H, Xie Z, Liu Q, Liang Y, et al. (2007) Phosphatidylinositol 3-kinase/protein kinase B pathway stabilizes DNA methyltransferase I protein and maintains DNA methylation. Cell Signal 19: 2255–2263.